Embryo Disorder
Conditions
Brief summary
IVF is the most commonly employed form of assisted reproductive technologies (ART) for the 10-15% of couples who face difficulties becoming pregnant. Many individuals elect to have their IVF-derived embryos analyzed using pregenetic implantation testing for aneuploidies (PGT-A). The use of PGT-A is particularly beneficial for patients at higher risk for aneuploidy, such as those of advanced maternal age and those faced with recurrent pregnancy loss or recurrent implantation failure. Segmental aneuploidies are generated when a small piece of a chromosome is gained or lost during cell division, resulting in subchromosomal copy number (CN) changes. The frequency of segmental aneuploidies during the cleavage stage varies between studies, from as low as 3.9% to 15% and up to 70 % with no reported correlation with maternal age. This can be explained by the fact that, unlike whole chromosome aneuploidies, segmental aneuploidies most often involve paternally inherited chromosomes.
Interventions
OTHERPreimplantation Genetic Testing for Aneuploidy
PGT-A typically involves the biopsy of three to eight cells from the developing embryo after approximately five days of culture. This technology also allows for the identification of segmentally aneuploid embryos.
Sponsors
Clinique Ovo
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 43 Years
Inclusion criteria
* IVF cycle completed at clinique ovo * Maternal age between 18 to 43 years included * PGT-A done on all embryos * Recent DFI within 1 year of the IVF cycle
Exclusion criteria
* Sperm donation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DFI association and aneuploidy | Up to 3 weeks after embryo fertilization | Segmental aneuploidy is associated with high levels of sperm DNA fragmentation index |
Countries
Canada
Outcome results
None listed